The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of July 2022. This month there are four guidelines and one technology appraisal that impact upon primary care.
The Pneumonia in adults: diagnosis and management guideline has been reinstated. It was temporarily withdrawn in May 2020 because of the COVID-19 pandemic. It covers diagnosing and managing pneumonia in adults who do not have COVID-19. It aims to improve accurate assessment and diagnosis of pneumonia to help guide antibiotic prescribing and ensure that people receive the right treatment.
The Social, emotional and mental wellbeing in primary and secondary education guideline has been published. It covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.
The Melanoma: assessment and management guideline has been updated. It covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. The update includes recommendations on genetic testing, staging, surgery.
The Urinary tract infection in under 16s: diagnosis and management guideline has been published. It covers diagnosing and managing first or recurrent upper or lower urinary tract infection (UTI) in babies, children and young people under 16. It aims to achieve more consistent clinical practice, based on accurate diagnosis and effective management.
The Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides technology appraisal has been published. This treatment is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:
- established cardiovascular disease (secondary prevention), defined as a history of any of the following:
- acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
- coronary or other arterial revascularisation procedures
- coronary heart disease
- ischaemic stroke
- peripheral arterial disease, and
- low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Drug Safety Update - July 2022||CKS Updates - July 2022 »|